Please login to the form below

Not currently logged in
Email:
Password:

kidney disease

This page shows the latest kidney disease news and features for those working in and with pharma, biotech and healthcare.

Protalix, Chiesi’s monthly treatment PRX-102 shows benefit in Fabry disease

Protalix, Chiesi’s monthly treatment PRX-102 shows benefit in Fabry disease

Fabry disease is a rare disorder in which patients inherit a deficiency of the α–Galactosidase–A enzyme. ... Fabry disease is a rare inherited disorder. Patients inherit a deficiency of the α–Galactosidase–A enzyme that results in the breakdown

Latest news

More from news
Approximately 22 fully matching, plus 142 partially matching documents found.

Latest Intelligence

  • AstraZeneca’s focus on diagnosing and managing chronic kidney disease AstraZeneca’s focus on diagnosing and managing chronic kidney disease

    People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care. ... AstraZeneca's R&D centre in Cambridge, UK. Moderate to severe chronic kidney disease (CKD) is an under-recognised public health

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    4. Vadadustat is an inhibitor of hypoxiainducible factor (HIF)-prolyl hydroxylase (HIF-PH) from Akebia Therapeutics/ Mitsubishi Tanabe Pharma/Otsuka that targets anaemia in chronic kidney disease (CKD). ... Hypercholesterolemia is a major risk of

  • Case study: What we're made of Case study: What we're made of

    If we don’t drink enough water, it can lead to headaches, constipation, tiredness and more serious problems, such as urinary infections and kidney disease. ... This could be a side effect of a condition such as stroke, motor neurone disease, multiple

  • 25 Women Leaders in UK Healthcare 25 Women Leaders in UK Healthcare

    The firm has just signed a long-term collaboration with AZ for the discovery of new drugs for chronic kidney disease and idiopathic pulmonary fibrosis (IPF). ... disease and applying machine learning, artificial intelligence and collapsing analysis to

  • Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019 Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

    of JAK proteins is an established method of controlling the symptoms of this disease. ... The sales forecast for Zolgensma is $2.09bn. Roxadustat, from AstraZeneca, FibroGen and Astellas, targets anaemia in chronic kidney disease (CKD).

More from intelligence
Approximately 1 fully matching, plus 20 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 7 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Madmicrobe Studios

MadMicrobe is an award-winning team of certified medical illustrators creating animations that draw audiences into a world of suspense, excitement,...

Latest intelligence

How a design mindset can lead to better medical outcomes
By adopting a design philosophy, healthcare companies can develop communications that allow healthcare professionals (HCPs) to better meet the needs of their patients. Imaginatively designed content combined with patient insights...
How does the government plan to reshape the NHS?
Oli Hudson, of Wilmington Healthcare, explores the government’s new white paper, which proposes key reforms for health and social care...
Want to give perfect client service? Tough luck, you’re human
In this article an ex-client of mine, Liz Skrbkova, and I explore the (unhelpful) pressures of trying to perfect the client-agency relationship...

Infographics